These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 33946100

  • 1. α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.
    Harstad E, Shults J, Barbaresi W, Bax A, Cacia J, Deavenport-Saman A, Friedman S, LaRosa A, Loe IM, Mittal S, Tulio S, Vanderbilt D, Blum NJ.
    JAMA; 2021 May 25; 325(20):2067-2075. PubMed ID: 33946100
    [Abstract] [Full Text] [Related]

  • 2. Adverse Effects of α-2 Adrenergic Agonists and Stimulants in Preschool-age Attention-deficit/Hyperactivity Disorder: A Developmental-Behavioral Pediatrics Research Network Study.
    Loe IM, Blum NJ, Shults J, Barbaresi W, Bax A, Cacia J, Deavenport-Saman A, Friedman S, LaRosa A, Mittal S, Vanderbilt D, Harstad E.
    J Pediatr; 2023 Jun 25; 257():113325. PubMed ID: 36649794
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
    Osland ST, Steeves TD, Pringsheim T.
    Cochrane Database Syst Rev; 2018 Jun 26; 6(6):CD007990. PubMed ID: 29944175
    [Abstract] [Full Text] [Related]

  • 4. Association of Coexisting Conditions, Attention-Deficit/Hyperactivity Disorder Medication Choice, and Likelihood of Improvement in Preschool-Age Children: A Developmental Behavioral Pediatrics Research Network Study.
    Deavenport-Saman A, Vanderbilt DL, Harstad E, Shults J, Barbaresi W, Bax A, Cacia J, Friedman S, LaRosa A, Loe I, Mittal S, Blum N.
    J Child Adolesc Psychopharmacol; 2022 Aug 26; 32(6):328-336. PubMed ID: 35787014
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
    Childress A, Hoo-Cardiel A, Lang P.
    Expert Opin Pharmacother; 2020 Mar 26; 21(4):417-426. PubMed ID: 31971448
    [Abstract] [Full Text] [Related]

  • 6. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.
    Pharmacoeconomics; 2012 Aug 01; 30(8):e1-15. PubMed ID: 22788263
    [Abstract] [Full Text] [Related]

  • 7. Common Use of Stimulants and Alpha-2 Agonists to Treat Preschool Attention-Deficit Hyperactivity Disorder: A DBPNet Study.
    Blum NJ, Shults J, Harstad E, Wiley S, Augustyn M, Meinzen-Derr JK, Wolraich ML, Barbaresi WJ.
    J Dev Behav Pediatr; 2018 Sep 01; 39(7):531-537. PubMed ID: 29851669
    [Abstract] [Full Text] [Related]

  • 8. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.
    McCracken JT, McGough JJ, Loo SK, Levitt J, Del'Homme M, Cowen J, Sturm A, Whelan F, Hellemann G, Sugar C, Bilder RM.
    J Am Acad Child Adolesc Psychiatry; 2016 Aug 01; 55(8):657-666.e1. PubMed ID: 27453079
    [Abstract] [Full Text] [Related]

  • 9. Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy.
    Schneider G, Banaschewski T, Feldman BL, Gustafsson PA, Murphy B, Reynolds M, Coghill DR, Spalding WM.
    J Child Adolesc Psychopharmacol; 2019 May 01; 29(4):285-304. PubMed ID: 30942617
    [Abstract] [Full Text] [Related]

  • 10. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR.
    J Child Adolesc Psychopharmacol; 2009 Oct 01; 19(5):501-10. PubMed ID: 19877974
    [Abstract] [Full Text] [Related]

  • 11. Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder.
    Michelini G, Lenartowicz A, Vera JD, Bilder RM, McGough JJ, McCracken JT, Loo SK.
    J Am Acad Child Adolesc Psychiatry; 2023 Apr 01; 62(4):415-426. PubMed ID: 35963559
    [Abstract] [Full Text] [Related]

  • 12. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
    Sallee FR.
    Postgrad Med; 2010 Sep 01; 122(5):78-87. PubMed ID: 20861591
    [Abstract] [Full Text] [Related]

  • 13. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
    Chan E, Fogler JM, Hammerness PG.
    JAMA; 2016 May 10; 315(18):1997-2008. PubMed ID: 27163988
    [Abstract] [Full Text] [Related]

  • 14. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
    Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH.
    Pediatrics; 2003 Nov 10; 112(5):e404. PubMed ID: 14595084
    [Abstract] [Full Text] [Related]

  • 15. ▼Guanfacine for ADHD in children and adolescents.
    Drug Ther Bull; 2016 May 10; 54(5):56-60. PubMed ID: 27173784
    [Abstract] [Full Text] [Related]

  • 16. Polypharmacy in the Management of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Review and Update.
    Baker M, Huefner JC, Bellonci C, Hilt R, Carlson GA.
    J Child Adolesc Psychopharmacol; 2021 Apr 10; 31(3):148-163. PubMed ID: 33600217
    [Abstract] [Full Text] [Related]

  • 17. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
    Molife C, Bernauer MJ, Farr AM, Haynes VS, Kelsey D.
    Postgrad Med; 2012 Sep 10; 124(5):7-22. PubMed ID: 23095422
    [Abstract] [Full Text] [Related]

  • 18. Young Children with Attention-Deficit/Hyperactivity Disorder and/or Disruptive Behavior Disorders Are More Frequently Prescribed Alpha Agonists Than Stimulants.
    Mittal S, Boan AD, Kral MC, Lally MD, van Bakergem K, Macias MM, LaRosa A.
    J Child Adolesc Psychopharmacol; 2020 Mar 10; 30(2):81-86. PubMed ID: 31621385
    [Abstract] [Full Text] [Related]

  • 19. Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.
    Huang YS, Tsai MH.
    CNS Drugs; 2011 Jul 10; 25(7):539-54. PubMed ID: 21699268
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
    Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A.
    Lancet Psychiatry; 2018 Sep 10; 5(9):727-738. PubMed ID: 30097390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.